X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Navicixizumab is an anti-DLL4/VEGF bispecific antibody product candidate that demonstrated antitumor activity in patients who were previously treated with Avastin® (bevacizumab) in a Phase 1b clinical trial.
Lead Product(s): Navicixizumab,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
Overall response rate (ORR) of 43% and median duration of response of 6 months seen with an anti-DLL4/VEGF bispecific antibody, navicixizumab in combination with paclitaxel heavily pretreated platinum-resistant ovarian cancer patients.
Lead Product(s): Navicixizumab,Paclitaxel
Therapeutic Area: Oncology Product Name: OMP-305B83
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab.
Lead Product(s): Navicixizumab
Therapeutic Area: Oncology Product Name: OMP-305B83
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: OncXerna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 09, 2021
Details:
Under the terms and conditions of the agreement, Oncologie receives exclusive global license to develop and commercialize navicixizumab.
Lead Product(s): Navicixizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Oncologie
Deal Size: $306.0 million Upfront Cash: $4.0 million
Deal Type: Licensing Agreement January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
